Patents by Inventor Christian F. Ockenhouse
Christian F. Ockenhouse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9592282Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.Type: GrantFiled: July 16, 2007Date of Patent: March 14, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
-
Patent number: 9364525Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.Type: GrantFiled: July 16, 2007Date of Patent: June 14, 2016Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
-
Publication number: 20150232950Abstract: The disclosure provides a multiplex real-time PCR method for determining the absolute quantification of Plasmodium parasites within a sample, and in some instances, as a measure of parasites/?l. Further, the disclosure provides a method of determining the strain of malaria within a sample.Type: ApplicationFiled: February 18, 2015Publication date: August 20, 2015Inventors: Edwin Kamau, Christian F. Ockenhouse, Karla C. Feghali, Saba Alemayehu
-
Patent number: 8697856Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: GrantFiled: August 3, 2012Date of Patent: April 15, 2014Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Anjali Yadava, Christian F. Ockenhouse
-
Publication number: 20120301497Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: August 3, 2012Publication date: November 29, 2012Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Patent number: 8258280Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: GrantFiled: July 9, 2010Date of Patent: September 4, 2012Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Anjali Yadava, Christian F. Ockenhouse
-
Publication number: 20110189218Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: July 9, 2010Publication date: August 4, 2011Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Patent number: 7790186Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: GrantFiled: January 18, 2006Date of Patent: September 7, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Anjali Yadava, Christian F. Ockenhouse
-
Publication number: 20100150998Abstract: The present invention relates to a novel lipoprotein particle, methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, compositions/vaccines containing the particle or antibodies against the protein particle such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. In particular it relates to an immunogenic protein particle comprising the following monomers: a. a fusion protein comprising sequences derived from a CS protein of P. vivax and the S antigen of Hepatitis B (CSV-S), and b. a fusion protein comprising sequences derived from CS protein of P. falciparum and S antigen of Hepatitis B (RTS), and c. optionally the S antigen derived from Hepatitis B.Type: ApplicationFiled: July 16, 2007Publication date: June 17, 2010Applicants: GLAXOSMITHKLINE BIOLOGICALS S.A., THE U.S.OFA. AS REPRESENTED BY THE SECRETARY OF THE ARMYInventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
-
Publication number: 20100062028Abstract: The present invention relates to a novel hybrid/fusion protein derived from the CS protein of Plasmodium vivax (P. vivax), methods for preparing and purifying the same, its use in medicine, particularly in the prevention of malarial infections, for example those caused by P. vivax, compositions/vaccines containing the protein or antibodies against the protein such as monoclonal or polyclonal antibodies and use of the same, particularly in therapy. The invention also extends to lipoprotein particles of said hybrid protein and formulations/vaccines comprising the same and use thereof. In particular it relates to an immunogenic hybrid fusion protein comprising: a. at least one repeat unit derived from the repeating region of a type I circumsporozoite protein of P. vivax, b. at least one repeat unit derived from the repeating region of a type II circumsporozoite protein of P. vivax, and surface antigen S derived from Hepatitis B virus, or a fragment thereof.Type: ApplicationFiled: July 16, 2007Publication date: March 11, 2010Inventors: Joseph D. Cohen, Martine Marchand, Christian F. Ockenhouse, Anjali Yadava
-
Publication number: 20090196883Abstract: Described in this application is a synthetic P. vivax circumsporozoite protein useful as a diagnostic reagent, for antibody production, and as a vaccine protective against infection with any strain of P. vivax.Type: ApplicationFiled: January 18, 2006Publication date: August 6, 2009Inventors: Anjali Yadava, Christian F. Ockenhouse
-
Patent number: 6641815Abstract: In this application is described the expression cloning and functional characterization of the CD36-binding domain of Sequestrin. Sequestrin is a surface protein of 215-250 kD size which does not vary in size between parasite strains. The Sequestrin gene appears to be single-copy-number within the genome; noncytoadherent laboratory parasite strains carry the sequestrin gene but fail to express the protein. Sequestrin binds with high affinity to CD36. Sequestrin protein and sequence can be used as a diagnostic, prognostic, and therapeutic tool.Type: GrantFiled: July 13, 1999Date of Patent: November 4, 2003Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Patrick E. Duffy, Christian F. Ockenhouse
-
Publication number: 20020042382Abstract: In this application is described the expression cloning and functional characterization of the CD36-binding domain of Sequestrin. Sequestrin is a surface protein of 215-250 kD size which does not vary in size between parasite strains. The Sequestrin gene appears to be single-copy-number within the genome; noncytoadherent laboratory parasite strains carry the sequestrin gene but fail to express the protein. Sequestrin binds with high affinity to CD36. Sequestrin protein and sequence can be used as a diagnostic, prognostic, and therapeutic tool.Type: ApplicationFiled: July 13, 1999Publication date: April 11, 2002Inventors: PATRICK E. DUFFY, CHRISTIAN F. OCKENHOUSE
-
Patent number: 6310046Abstract: In this application is described the expression cloning and functional characterization of the CD36-binding domain of Sequestrin. Sequestrin is a surface protein of 215-250 kD size which does not vary in size between parasite strains. The Sequestrin gene appears to be single-copy-number within the genome; noncytoadherent laboratory parasite strains carry the sequestrin gene but fail to express the protein. Sequestrin binds with high affinity to CD36. Sequestrin protein and sequence can be used as a diagnostic, prognostic, and therapeutic tool.Type: GrantFiled: November 17, 1995Date of Patent: October 30, 2001Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Patrick E. Duffy, Christian F. Ockenhouse